- Details
- Defining optimal therapeutic sequencing strategies in prostate cancer (PC) is challenging and may be assisted by artificial intelligence (AI)-based tools for an analysis of the medical literature. To demonstrate that INSIDE PC can help clinicians query the literature on therapeutic sequencing in PC and to develop previously unestablished practices for evaluating the outputs of AI-based support pla...
|
- Details
- Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin's potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing canc...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
- Details
- Yu-Wei Chen discusses his research focusing on androgen receptor (AR) and neuroendocrine signatures in prostate cancer using the Caris database. This study classifies prostate tumors into four molecular subgroups, revealing significant insights into their distinct behaviors and treatment responses. Dr. Chen's findings challenge the conventional histological classifications by demonstrating variati...
|
- Details
- Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all demogra...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
|
- Details
- Deepak Kilari discusses a Phase II trial exploring the combination of enzalutamide with five alpha-reductase inhibitors (ARIs) for castrate-sensitive prostate cancer. Driven by observations from geriatric oncology, the study seeks alternatives to androgen deprivation therapy (ADT) for older, frail men who struggle with its side effects. The trial examines whether enzalutamide combined with dutaste...
|
- Details
- Anthony Joshua presents the findings of the MAST trial, a decade-long investigation into the use of metformin for men with low-risk prostate cancer under active surveillance. Conducted across 12 Canadian centers, this randomized Phase III study involved 408 men and aimed to determine if metformin could delay cancer progression. Despite earlier promising studies suggesting potential benefits, the t...
|
- Details
- Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation the...
|
- Details
- Alicia Morgans speaks with Dan Petrylak about his phase 1 study on a new androgen receptor (AR) degrader, ARV-766. This study explores the potential of AR degraders to effectively target and dismantle androgen receptors in prostate cancer cells, particularly those resistant to conventional therapies. Dr. Petrylak highlights the journey of ARV-766, a second-generation PROTAC drug designed to degrad...
|
